Loading...
  • prognosis
  • Molecular methods such as gene expression profiling (GEP), high-resolution array comparative genomic hybridization, and next-generation sequencing hold great promise in elucidating the pathogenesis and prognosis of DLBCL, but these methods are not widely available due to substantial cost, technical complexity, and requirement for fresh and frozen tissue. (lymphomation.org)
  • Next-generation sequencing has detected numerous mutations in patients with DLBCL, but whether any of those mutations are important for prognosis, alone or in combination, is not yet answered. (lymphomation.org)
  • The most common cytogenetic abnormality in DLBCL (up to 30% of cases) is a translocation involving the BCL6 at 3q27, which has been found by some studies, but not others, associated with a better prognosis. (clinicalpainadvisor.com)
  • Expression of the polycomb-group gene BMI1 is related to an unfavourable prognosis in primary nodal DLBCL. (uva.nl)
  • Microarray studies showed that patients with DLBCL with a germinal centre B cell-like (GCB) phenotype have a better prognosis than those with an activated B cell-like (ABC) phenotype. (uva.nl)
  • The BMI1 proto-oncogene was identified as one of the genes present in the signature of the ABC type of DLBCL, associated with a poor prognosis. (uva.nl)
  • adult patients
  • The applications to the regulatory bodies in the US and the EU were based on data from the Novartis-sponsored global clinical trial programme of Kymriah in children and young adults with r/r B-cell ALL and adult patients with r/r DLBCL , which demonstrated the efficacy and safety of Kymriah across studies, as well as the results from the pivotal Phase II JULIET clinical trial. (thefreedictionary.com)
  • The submission is based on results from the Novartis-sponsored, global, multi-center Phase II JULIET study (NCT02445248), the first global, multi-center registration study for Kymriah in adult patients with r/r DLBCL. (prnewswire.com)
  • aggressive
  • These patients likely represent those with the most aggressive subset of DLBCL who did not survive long enough to generate adequate CAR T-cell doses or came off study for reasons mostly related to disease progression. (ascopost.com)
  • Transplant
  • Patients enrolled on the trial have DLBCL and did not respond to their last line of chemotherapy or progressed within 12 months of an autologous hematopoietic stem cell transplant, says Locke. (onclive.com)
  • data
  • Data from the literature suggest an encouraging activity of R-chemo+ bortezomib in non GCB-derived DLBCL, although in small series. (centerwatch.com)